Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$22.17 - $51.8 $4.27 Million - $9.97 Million
192,459 New
192,459 $9.94 Million
Q1 2022

May 16, 2022

SELL
$22.22 - $39.12 $2.37 Million - $4.17 Million
-106,583 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$18.38 - $40.5 $1.96 Million - $4.32 Million
106,583 New
106,583 $3.88 Million
Q2 2021

Aug 16, 2021

SELL
$9.59 - $50.88 $50,759 - $269,307
-5,293 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$49.53 - $68.4 $262,162 - $362,041
5,293 New
5,293 $271,000

Others Institutions Holding CCXI

About ChemoCentryx, Inc.


  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.